| The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Management of myelodysplastic syndromes after failure of response to hypomethylating agents |
|
Therapeutic Advances in Hematology |
Myelodysplastic Syndromes (MDS) |
| Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| MDS with 5q deletion and rare cKIT positive mastocytosis: a diagnostic and therapeutic challenge |
|
BMJ Case Reports |
Myelodysplastic Syndromes (MDS) |
| Use of Immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis |
|
Haemotologica |
Myelodysplastic Syndromes (MDS) |
| Flaming and fanning: The Spectrum of inflammatory influences in myelodysplastic syndromes |
|
Blood Reviews |
Myelodysplastic Syndromes (MDS) |
| Eltrombopag for refractory severe aplastic anemia: dosing, duration, long term outcomes and clonal evolution |
|
Blood |
Aplastic Anemia |
| Getting personal with myelodysplastic syndromes: is now the right time? |
|
Expert Review of Hematology |
Myelodysplastic Syndromes (MDS) |
| Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study |
|
Haematologica |
Aplastic Anemia |
| A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS) |
|
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
